China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...
Zhongchao Partners with Natco Pharma to Distribute Drugs in China
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...
By-Health to Establish Nutrition Research Center with Shanghai Institute
China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...
Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...
Everest Medicines Outlines Strategic Plans for Expansion and Growth
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...
Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd...
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...